NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
Children's Oncology Group
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
N.N. Petrov National Medical Research Center of Oncology